Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24359182 | 0.85 | NR1H2 (0.43) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL27221499 | 0.84 | USP2 (0.40) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL24359199 | 0.83 | HTT (0.38) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL346187 | 0.81 | DDB1 (0.40) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL346150 | 0.80 | JAK1 (0.43) | GPR119JAK2JAK1ALDH1A1 | |
| SCHEMBL26984467 | 0.80 | USP2 (0.44) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL30275105 | 0.78 | USP2 (0.43) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL34467509 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL29021755 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN | |
| SCHEMBL30352914 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2NR1H2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166660-A1 | KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166660-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | USP2 1615/4885SMN1; SMN2 2322/4885NR1H2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.